DMC, P., GM, T., K, C., MTY, C., TW, C., RWM, K., . . . PKF, C. (2024). Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: Consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology. Frontiers in oncology, 14, 1345322. https://doi.org/10.3389/fonc.2024.1345322
Chicago Style (17th ed.) CitationDMC, Poon, et al. "Addressing the Risk and Management of Cardiometabolic Complications in Prostate Cancer Patients on Androgen Deprivation Therapy and Androgen Receptor Axis-targeted Therapy: Consensus Statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology." Frontiers in Oncology 14 (2024): 1345322. https://doi.org/10.3389/fonc.2024.1345322.
MLA (9th ed.) CitationDMC, Poon, et al. "Addressing the Risk and Management of Cardiometabolic Complications in Prostate Cancer Patients on Androgen Deprivation Therapy and Androgen Receptor Axis-targeted Therapy: Consensus Statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology." Frontiers in Oncology, vol. 14, 2024, p. 1345322, https://doi.org/10.3389/fonc.2024.1345322.
